CARLSBAD, Calif., Sept. 4, 2026, 6:47 p.m. EDT — Ionis Pharmaceuticals, Inc. NASDAQ:IONS lost an estimated $877 million of market value after hours Friday. Its shares fell 9.1% to $52.81 after a pivotal heart-drug trial failed.
The selloff exceeds the maximum $625 million of contingent Royalty Pharma payments disclosed by Ionis. That comparison tells only part of the story. Investors also repriced retained pelacarsen royalties and confidence in the cardiovascular program.
Novartis AG NYSE:NVS developed the medicine and funded the Phase 3 study. Its U.S. shares dropped another 5.0% after hours, following a 1.9% regular-session decline.
- Pelacarsen lowered lipoprotein(a) but failed to reduce major cardiovascular events.
- The Lp(a)HORIZON trial enrolled 8,323 patients with established heart disease.
- Ionis traded as low as $50.78, then recovered to $52.81.
- Royalty Pharma owns 25% of future pelacarsen royalties under a 2023 transaction.
Ionis said the trial missed its primary endpoint against placebo. The measure combined cardiovascular death, nonfatal heart attack, nonfatal stroke and urgent coronary procedures requiring hospitalization.
Pelacarsen substantially reduced Lp(a), an inherited risk factor. That biological effect did not produce lower cardiovascular risk in the overall population. The companies reported an acceptable safety profile.
“These are not the results we hoped for,” Novartis development chief Shreeram Aradhye said. Full data will come at an upcoming medical congress. Neither company disclosed a filing plan Friday.
Ionis lost almost $900 million after the result
Regular close and selected after-hours trades, Sept. 4, 2026
Source: Yahoo Finance. Latest observation at . Thin after-hours trading can amplify moves.
The biology worked; the outcome did not
The global study randomized 8,323 patients with elevated Lp(a) and established cardiovascular disease. They were already receiving guideline-directed care. Its registered design made clinical events the decisive test.
That distinction matters for the wider field. Lowering a laboratory marker is useful only if patients benefit. Friday’s topline result weakens the simplest version of that investment case.
Important detail is still missing. The companies gave no event counts, hazard ratio or subgroup results. Investors cannot yet judge whether any narrower population showed a credible signal.
The market cut goes beyond one contingent payment
Preliminary Ionis value bridge and pelacarsen royalty structure
The royalty contract magnifies the miss
Ionis discovered pelacarsen and licensed it to Novartis in 2019. The economics changed again in 2023. Royalty Pharma paid $500 million for portions of Ionis’s future SPINRAZA and pelacarsen royalties.
Royalty Pharma receives 25% of any pelacarsen royalties. Ionis kept the remaining 75%. Ionis can also receive up to $625 million in further payments under the transaction.
Those payments carry conditions tied to pelacarsen approval or sales, sometimes by deadlines. Ionis has not quantified Friday’s effect on them. Its next accounting review may provide more clarity.
Ionis still has a commercial base
Pelacarsen is a licensed asset, rather than Ionis’s whole business. The company ended June with $2.1 billion of cash and short-term investments. It also sells two wholly owned medicines in the United States.
TRYNGOLZA generated $5 million of second-quarter U.S. sales. DAWNZERA produced $26 million. Their combined 2026 sales guidance runs from $210 million to $230 million.
The rest of Ionis now carries more weight
Commercial guidance, liquidity and the pre-result analyst view
Three paths from here
The base case is a reduced pelacarsen value and lower analyst targets. A narrower salvage case needs convincing subgroup data. That evidence is unavailable today.
A harsher outcome would spread the discount to other cardiovascular antisense programs. A better outcome rests on independent product launches and the broader pipeline. Ionis still targets cash-flow breakeven in 2028.
Risks: Friday’s prices came from thin after-hours trading. Full data may reveal nuances absent from the topline release. Commercial launches can also miss guidance, while clinical assets can fail without warning.
Friday settled one question: lowering Lp(a) did not cut events in the overall trial. The next valuation debate starts with what Ionis can earn without pelacarsen.
